Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6707301 | 0.89 | HTR2C (0.58) | HDAC4HDAC8HTR2CHTR2A | |
| SCHEMBL25691218 | 0.88 | ALDH1A1 (0.48) | HDAC4HDAC8HTR2CALDH1A1HTR2A | |
| SCHEMBL16951872 | 0.86 | HIF1A (0.41) | HDAC4HDAC8HIF1AHTR2CHTR2A | |
| SCHEMBL21145969 | 0.86 | MMP13 (0.43) | HDAC4HDAC8HIF1AHTR2CALDH1A1 | |
| SCHEMBL27017096 | 0.85 | ALDH1A1 (0.42) | HDAC4HDAC8HIF1AHTR2CALDH1A1 | |
| SCHEMBL6707933 | 0.82 | QDPR (0.53) | ALDH1A1MEN1KMT2A | |
| SCHEMBL17660575 | 0.81 | CHRM4 (0.46) | — | |
| SCHEMBL16952484 | 0.80 | HTR2C (0.37) | HIF1AHTR2CALDH1A1HTR2AMEN1 | |
| SCHEMBL15713203 | 0.79 | HDAC4 (0.42) | HDAC4HDAC8HIF1AALDH1A1RAB9A | |
| SCHEMBL3378367 | 0.78 | DRD2 (0.46) | ALDH1A1MEN1KMT2ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018102-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY | Lhotse Bio, Inc (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240018102-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY | Lhotse Bio, Inc (US) | 2024-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018102-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY | LPAR1, LPAR2, LPAR5 | HDAC4 1370/4885HDAC8 650/4885HIF1A 3139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.